Jazz Pharmaceuticals (JAZZ) Expanded Access Program Suggests JZP-458 Launch is On Track - Cowen
Tweet Send to a Friend
Cowen analyst Ken Cacciatore reiterated an Outperform rating and $200.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ), saying they believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
